Form 4: Phibro CEO Sells $541K in Stock Under 10b5-1 Plan

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold over $541,000 worth of Class A Common Stock in pre-planned transactions.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On November 25, 2025, 7,040 shares were sold at a weighted average price of $43.9261, with prices ranging from $43.51 to $44.195.
• On November 26, 2025, an additional 5,280 shares were sold at a weighted average price of $44.0216, with prices ranging from $43.79 to $44.37.
• Following these transactions, BFI Co., LLC indirectly holds 33,840 shares, and Jack Bendheim directly holds 16,840 shares.
• The total value of shares sold across both transactions is approximately $541,632.

Sentiment

Score: 4

Explanation: While the sales were pre-planned under a 10b5-1 plan, significant insider selling by a CEO and 10% owner, even if routine, can still be interpreted as a slightly negative signal regarding future growth prospects or valuation by some investors. The pre-planned nature mitigates the negativity, preventing a lower score.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were not a reaction to recent negative company news.

Negatives

• Significant insider selling by a key executive (CEO, Director, 10% Owner) can be perceived negatively by the market, regardless of a 10b5-1 plan.
• The sales represent a reduction in the beneficial ownership of a significant insider.

Risks

• Investor perception of insider selling could lead to negative sentiment or downward pressure on the stock price.

Future Outlook

NA

Industry Context

This filing reports routine insider trading activity for Phibro Animal Health Corp, a company operating in the animal health and nutrition industry. Such transactions are common across all industries, though the specifics of the company's market position or competitive landscape are not detailed in this particular filing.

Related Party Transactions

• Jack Bendheim, as President and CEO, Director, and 10% Owner, exercises voting and dispositive power over BFI Co., LLC, which conducted the reported sales. This constitutes a related party transaction where Mr. Bendheim disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may perceive the insider selling as a signal, potentially influencing their investment decisions, though the 10b5-1 plan mitigates immediate concerns about new negative information.

Key Dates

Recommendation

The insider sales by the CEO and 10% owner, while substantial in value, were executed under a pre-arranged Rule 10b5-1 trading plan. This suggests the sales are for personal financial planning rather than a reaction to adverse company developments. Given the pre-planned nature, it doesn't necessarily signal a fundamental shift in the company's outlook, thus a 'hold' recommendation is appropriate, advising investors to maintain their current positions while monitoring future developments.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Selling, Form 4, 10b5-1 Plan, Stock Sale, CEO, Director, 10% Owner, Equity Transaction